Evolus Inc (NASDAQ:EOLS) Receives Average Rating of “Buy” from Analysts

Shares of Evolus Inc (NASDAQ:EOLS) have received a consensus rating of “Buy” from the eleven brokerages that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $14.25.

Several equities research analysts have issued reports on EOLS shares. BidaskClub lowered shares of Evolus from a “sell” rating to a “strong sell” rating in a report on Thursday, March 5th. SVB Leerink lowered their target price on shares of Evolus from $25.00 to $15.00 and set an “outperform” rating on the stock in a report on Friday, April 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Evolus in a report on Tuesday, May 12th. Barclays lowered their target price on shares of Evolus from $9.00 to $4.00 and set an “underweight” rating on the stock in a report on Wednesday, May 13th. Finally, Stifel Nicolaus lowered their target price on shares of Evolus from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, April 16th.

Evolus stock traded down $0.04 on Friday, hitting $5.56. The company’s stock had a trading volume of 929,316 shares, compared to its average volume of 943,423. The firm has a market cap of $188.88 million, a P/E ratio of -1.63 and a beta of 3.18. The company has a quick ratio of 5.02, a current ratio of 5.58 and a debt-to-equity ratio of 1.24. The company has a fifty day moving average price of $4.78 and a 200-day moving average price of $7.37. Evolus has a one year low of $3.12 and a one year high of $20.27.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.03). The business had revenue of $10.50 million during the quarter, compared to the consensus estimate of $16.91 million. Evolus had a negative net margin of 217.51% and a negative return on equity of 197.30%. Analysts anticipate that Evolus will post -2.68 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers lifted its position in Evolus by 11.2% during the 4th quarter. Rhumbline Advisers now owns 16,448 shares of the company’s stock worth $200,000 after buying an additional 1,651 shares in the last quarter. American International Group Inc. lifted its position in Evolus by 21.3% during the 4th quarter. American International Group Inc. now owns 11,568 shares of the company’s stock worth $141,000 after buying an additional 2,029 shares in the last quarter. Royal Bank of Canada lifted its position in Evolus by 55.6% during the 1st quarter. Royal Bank of Canada now owns 7,141 shares of the company’s stock worth $30,000 after buying an additional 2,553 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in Evolus by 19.7% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 18,549 shares of the company’s stock worth $77,000 after buying an additional 3,049 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY acquired a new position in Evolus during the 1st quarter worth about $83,000. Institutional investors and hedge funds own 42.43% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Read More: Trade War

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.